Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing.
Abstract
The multikinase inhibitor midostaurin is the first targeted therapy to improve overall survival (OS) in patients with acute myeloid leukemia (AML) and the FLT3 mutation. Midostaurin plus standard chemotherapy improved survival compared with placebo plus chemotherapy as an upfront treatment for high-risk patients with AML and FLT3 mutations.
Patients and physicians have waited for new drugs for AML since the 1990s, so the results of the CALGB...
Paper Details
Title
Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing.
Published Date
Feb 1, 2016
Journal
Volume
9
Issue
Spec Issue
Pages
1 - 21
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History